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Abstract: Murine reconstitution assays were used to 
investigate the effects of recombinant human interleukin-
7 (rhIL-7) on myeloid and lymphoid precursors and on 
bone marrow engraftment. Reconstitution with bone 
marrow from rhIL-7-treated mice results in a 3.4-fold 
decrease in total colony-forming unit-spleen (CFU-S) ac­
tivity (day 9) and an 18.1- and 11.9-fold decrease in its 
ability to generate thymocytes and splenic B lineage cells, 
respectively. In contrast, after reconstitution with spleno- 
cytes from rhIL-7-treated mice, CFU-S activity increased 
23.6-fold (day 9) and the thymocyte and splenic B lineage 
cell regenerative capacity increased by 4.0- and 3.2-fold, 
respectively. In addition, CD43Iow+, B220lowf cells that 
contain pre-pro-B cells and pro-B cells were expanded 
two- to threefold and Ig(X‘, B220+, CD2" and Ig|T, B220+, 
CD2+ B lineage cells were expanded approximately 10- 
fold and 10- to 45-fold (depending on the tissue exam­
ined), respectively, after rhIL-7 treatment. Administration 
of rhIL-7 to irradiated mice transplanted with bone mar­
row resulted in accelerated T cell and B cell reconstitu­
tion by up to 2-4 weeks. Thus, rhIL-7 administration 
affects the distribution of myeloid and lymphoid precur­
sors. Moreover, rhIL-7 administration accelerates murine 
bone marrow cell engraftment and therefore may be 
useful in reducing the engraftment time in bone marrow
transplant patients. J. Leukoc. Biol 58: 151-158; 1995.
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INTRODUCTION
«
The differentiation of cells of the various hemopoietic 
lineages involves a complex and as yet incompletely un­
derstood series of events. In recent years there have been 
advances in isolating and expressing cytokines known to 
be involved in hematopoiesis. Granulocyte-macro- 
phage-colony-stimulating factor (GSF), interleukin-3 (IL-
3), granulocyte-CSF, CSF-1, and IL-6 have been shown to 
be directly stimulatory to myeloid progenitor cells [1, 2]. 
In contrast, the factors that regulate lymphopoiesis at the 
progenitor cell level are largely unknown, despite a large 
body of evidence showing significant effects of various ILs 
on mature T cells and B cells.
The development of a long-term B lineage culture sys­
tem allowed the demonstration of sustained lymphopoi­
esis in vitro [3, 4], whereby populations of pro-B and 
pre-B cells developed over a period of several months. By 
using this technique IL-7 was originally described as a 
bone marrow stromal cell-derived factor that could sup­
port the proliferation of B cell precursors from Whidock- 
Witte bone marrow cultures [5], thus demonstrating its 
growth/regulatory function in lymphopoiesis. Murine 
and human IL-7 cDNA have both been cloned, se­
quenced, and expressed [6, 7] and there is 60% homology 
at the amino acid level. Northern blot analysis of various 
murine and human tissues showed that the IL-7 gene is 
transcribed not only in the bone marrow, but also in the 
spleen and the thymus [6].
IL-7 was initially shown to be a B cell lineage growth 
factor with preferential stimulating effects on the prolif­
eration of B cell precursors [6, 8, 9]. Subsequently, it was 
found that ILr7 increased the number of CD3+ cells in 
bone marrow cultures [10] and also supported the growth 
of thymocytes [11-13], in particular the CD4CD8", 
CD4+CD8“, and CD4'CD8+ subsets [14]. IL-7 also was 
shown to act as a co-stimulator for peripheral T lympho­
cytes, in concert with mitogen or antigen in vitro [15, 16]. 
In vitro, IL-7 has been shown to enhance CSF-induced 
proliferation of myeloid colony formation [17].
The in vivo effects of IL-7 administration using murine 
systems also have been examined. Normal mice treated 
with recombinant murine IL-7 (rmIL-7) have increased 
lymphocyte numbers [18] and cyclophosphamide-treated 
mice were able to reconstitute the lymphocyte compart­
ment more rapidly with rmIL-7 treatment [19]. Further-
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more, administration of recombinant human IL-7 (rhlL- 
7) to sublethally irradiated mice resulted in accelerated 
repopulation of T and B lymphocytes and some immature 
myeloid lineage cells [20], Our laboratory has previously 
demonstrated that administration of rhIL-7 to mice in­
duced exportation of single lineage colony-forming units- 
culture (CFU-c) and multilineage CFU-granulocyte, 
erythroid, monocyte, and megakaryocyte (CFU-GEMM) 
colony-generating myeloid progenitors from the bone 
marrow to the spleen that resulted in a 90% decrease in 
bone marrow myeloid progenitors and a Fivefold increase 
in the spleen [21, 22]. We also have shown that the ad­
ministration of rhIL-7 resulted in a three- to fivefold in-
n
crease in leukocytes in spleen and lymph nodes due to an 
increase in all major mature leukocyte subsets (B, T, and 
natural killer cells and macrophages) with a dispropor­
tionate increase in pre-B cells and CD8+ T cells [23]. 
Furthermore, T cells in rhIL-7-treated mice had enhanced 
and accelerated abilities to respond to various stimuli
[23].
In this study we examined the effects of rhIL-7 admini­
stration on early myeloid and lymphoid precursors by 
using in vivo reconstitution assays. Our data demonstrate 
that administration of rhIL-7 to mice results in a relocali­
zation of the earliest (CFU-spleen [CFU-S] generating) 
myeloid progenitors and of lymphoid precursors from 
the bone marrow to the spleen. These data also demon­
strate an increase in pre-pro-B cells and pro-B cells and an 
increase in CD2+ and CD2' B cell precursors after rhIL-7 
treatment. In addition, administration of rhIL-7 to 
lethally irradiated mice after bone marrow transfer was 
able to accelerate bone marrow engraftment by up to 2-4 
weeks. Thus, these data demonstrate that IL-7 has pro­
found effects on both myeloid and lymphoid precursors 
and suggest that IL-7 may have a valuable role in acceler­
ating bone marrow engraftment in transplant patients.
MATERIALS AND METHODS
Mice
Six- to 10-week-old female C57BL/6 (Ly 5,2) or C57BL/6-Ly 5,1 
congenie mice were obtained from the Animal Production Area of the 
National Cancer Institute-Frederick Cancer Research and Development 
Center (Frederick, MD) and were maintained under specific pathogen- 
free conditions.
Cytokine treatment
Recombinant human IL-7, generously supplied by Sterling Winthrop, 
Inc. (Collegeville, PA), had a specific biological activity of 2-5 x 107 
U/mg, as measured by the proliferation of a murine pre-B cell line [7]; 
the endotoxin levels were <2 endotoxin U/mg of rhIL-7. Mice were 
injected intrap e rito ne ally twice daily with Hanks’ balanced salt solution 
(HBSS) containing 0.1% normal mouse serum (NMS) as a vehicle con­
trol or with 5 or 10 )Xg/injection of rhIL-7 in HBSS and 0.1% NMS at
0.5 ml/injection. This regimen was based on observations from our 
previous studies [21, 23].
Cell suspension preparation
Bone marrow cells, splenocytes, and thymocytes were prepared as pre­
viously described [21, 23]. Erythrocytes in the bone marrow and spleno- 
cyte suspensions were rapidly lysed (5 s) with distilled water. After a final 
wash with HBSS, the cells were either injected intravenously into irradi­
ated recipients or labeled with antibodies for flow cytometric analysis 
(FCA).
CFU-S assay
The CFU-S assay was performed as described by Till and McCulloch
[24], Briefly, 6-week-old recipient mice were lethally irradiated (900
rads) by using a MARK 1 Irradiator affixed with a 302 attenuator (J.L. 
Shepherd, San Fernando, CA) containing a 137Cs source emitting 229 
rads/min, rested 3-4 h, then reconstituted intravenously with 2 x 105 
bone marrow cells or 5 x 105 splenocytes. Nine and 12 days later their 
spleens were removed, fixed in Bouin’s fixative, and scored for the 
presence of macroscopic colonies.
Reconstitution assay
Recipient mice were sublethally (750 rads) or lethally (900 rads) irradi­
ated 3-4 h before reconstitution. Recipients were injected intravenously 
with varying numbers of donor-origin bone marrow cells or splenocytes. 
At various times after reconstitution the recipients were euthanized and 
their thymi and spleens were removed for further analysis.
Immunofluorescence labeling and FCA
Three mice per group were used for each time point. Single cell suspen­
sions were labeled with antibody and FCA was performed as previously 
described [21]. Donor-origin and host-origin cells were detected with the 
monoclonal antibodies (mAb) reactive against Ly 5.1 (mouse IgG2a, 
clone A-20-1.7; Ref. 25) and Ly 5.2 (mouse IgG2a, clone 104-2.1; Ref. 
25), respectively, and developed with either fluorescein isothiocyanate 
(FITC)-conjugated, affinity-purified goat anti-mouse IgG and IgM (heavy 
and light chain specific) antibody (Kirkegaard & Perry Laboratories Inc., 
Gaithersburg, MD) for thymocytes or phycoerythrin-conjugated, affinity- 
purified goat anti-mouse IgG2a (Caltag Laboratories, South San Fran­
cisco, CA) for splenocytes. Donor-origin splenic myeloid cells were 
detected in two-color analysis by using the biotin-conjugated mAb clone 
RB6-8C5 (rat IgG2b, PharMingen, San Diego, CA) developed with strep- 
tavidin-REDei3 (GIBCO-BRL, Life Technologies, Inc., Gaithersburg, 
MD) combined with the anti-Ly 5.1 mAb developed as indicated above. 
The mAb RB6-8C5 detects the RB6-8C5 myeloid differentiation antigen, 
which is expressed on all granulocytes in increasing amounts as the cells 
mature. It also may be transiently expressed on cells undergoing macro­
phage differentiation [26].
Donor-origin splenic T cells were detected in two-color analysis by 
using the anti-CD 3 mAb 500A2 (hamster IgG; Ref. 27) developed with 
a FITOconjugated, affinity-purified goat anti-hamster IgG (heavy and 
light chain specific and mouse serum absorbed) antibody (Caltag Labo­
ratories) combined with the anti-Ly 5.1 mAb developed as indicated 
above. Donor-origin splenic B lineage cells (B220+) and mature B cells 
(surface Ig|¿+) were detected in three-color analysis by using FITC-conju- 
gated, affinity-purified goat anti-mouse IgM (|x heavy chain specific) 
antibody (FisherBiotech; Fisher Scientific, Orangeburg, NY) combined 
with phycoerythrin-conjugated anti-B220 mAb (rat IgG2a, clone RA3- 
6B2; PharMingen) and anti-Ly 5.1 mAb conjugated with biotin in our 
laboratory and developed with streptavidin-RED613. Two sets of antibod­
ies were used to examine immature B lineage cells. The first combina­
tion included FITC-conjugated anti-CD43 mAb (rat IgG2a, clone S7; 
originally produced by Gulley et al. [28] and conjugated by Randy 
Fischer, Biological Response Modifiers Program, National Cancer Insti­
tute, Frederick, MD) combined with phycoerythrin-conjugated anii-B220 
mAb and the second combination included FITC-conjugated anti-CD2 
mAb (rat IgG2b, clone RM2-5; PharMingen) combined with phyco­
erythrin-conjugated anti-B220 mAb and bio tin-conjugated, affinity-puri­
fied goat anti-mouse IgM (ji heavy chain specific) antibody (Vector 
Laboratories, Inc., Burlingame, CA) developed with streptavidin-REDfi70 
(GIBCO-BRL). All antibodies used were titered to determine optimal 
working dilutions and iso type-matched controls were used to determine 
the amount of nonspecific binding. All polyclonal antibodies were pre­
tested and found to be highly specific with no detectable cross-reactivi­
ties to Igs of other species, isotypes, or subclasses.
Statistical analysis
Results from representative experiments are expressed as the mean ± sd. 
The significance of alterations in the numbers of leukocytes obtained 
from various groups was determined by Student’s ¿-test.
RESULTS 
Effect of rhIL-7 on the frequency of CFU-S in bone 
marrow and spleen
Previous work in our laboratory demonstrated that rhIL-7 
administration to normal mice decreased the number of 
CFU-c and CFU-GEMM myeloid progenitors in the bone 
marrow and increased the number of these progenitors
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TABLE 1. Administration of rhIL-7 to Mice Alters the Capacity o f Spleen and Bone Marrow Cells to Generate CFU-S
Donor treatment
(organ). -
Cellularity of 
donor organ 
after treatmentt 
fxlO'V_______
No, of donor
cells
injected
1x10'5Ï
Number of
CFU-S/ recipient
Total -No. of CFU-S 
generated by donor cells
on a per organ basis
b
Day 9 Day 9 J3ay__12.
HBSS-bone marrow 
rhIL-7-bone marrow 
HBSS-spleen 
rhIL-7-spleen
14.6
32.0
49.6
252.0
2
2
5
5
15 ± 1 
2 ± 2C 
3± 1 
13 ± Ie
9 ± 3
3 ±3
4 ± 1 
12 ± 2C
1080 ± 61 
320 ± 320c 
278 ± 109 
6552 ± 504c
675 ± 201 
373 ± 403 
377 ± 129 
5846 ±982c
Donor C57BL/6-Ly 5.1 mice (10-55/group) were injected intraperitoneally with HBSS and 0.1% NMS or 10 (ig of rhIL-7, respectively, twice 
a day for 7 days. After cessation of treatment donor bone marrow cells or splenocytes were injected intravenously into five lethally (900 rads) 
irradiated C57BL/6 (Ly 5.2) recipients per group. On days 9 or 12 after transfer the spleens were removed from the recipients and the number 
of CFU-S were enumerated. Lethally, irradiated recipient controls that were injected only with HBSS had no CFU-S on days 9 or 12. Data represent
the mean ± SD.
aResults indicate the number of cells from a pool of mice divided by the number of mice.
^These data were calculated by multiplying the number of CFU-S per recipient spleen by the total mean cellularity of the donor organ (column
2) and dividing by the number of donor cells injected.
c Signifie an dy different from HBSS-treated controls (P<001).
in the spleens by exportation from the bone marrow to 
the spleen [21, 22]. To investigate the effect of rhIL-7 on 
even more immature erythro/myeloid progenitor cells, 
the in vivo CFU-S assay was performed. Donor C57BL/6- 
Ly 5.1 mice were injected intraperitoneally with HBSS 
and 0.1% NMS or 10 jig of rhIL-7 twice a day for 7 days. 
On the following day 2 X IO5 bone marrow cells or 5 X 
105 splenocytes from these mice were injected intrave­
nously into lethally irradiated (900 rads) C57BL/6 (Ly 
5.2)-recipient mice. On days 9 or 12 after transfer the 
spleens were removed from the recipient mice and CFU-S 
were enumerated. The results in Table 1 demonstrate 
that the number of CFU-S generated after transfer of 
bone marrow cells from rhIL-7-treated mice decreased by 
7.5-fold (day 9) when compared with the numbers gener­
ated after injection of HBSS and 0.1 % NMS-treated con­
trol cells. However, the number of CFU-S generated after 
transfer of splenocytes from rhIL-7-treated mice in­
creased by 4.3-fold (day 9) or 3.0-fold (day 12) when com­
pared with the numbers generated after the injection of 
HBSS and 0.1% NMS-treated control cells. Furthermore, 
because of the ability of rhIL-7 treatment to significantly 
increase, splenic cellularity [23] there was a 23.6-fold (day 
9) or 15.5-fold (day 12) increase in the CFU-S-generating 
capacity of splenocytes from rhIL-7-treated mice on a per 
organ basis (Table 1). Because rhIL-7 treatment does not 
decrease bone marrow cellularity [2 1], there was still a 
3.4-fold (day 9) decrease in CFU-S-generating capacity in 
bone marrow on a per organ basis from rhIL-7-treated 
mice.
Lymphocyte regeneration after transfer of bone marrow 
cells or splenocytes from rhlL-7-treated mice into 
irradiated recipients
To determine the effects of rhIL-7 on lymphoid progeni­
tors in the bone marrow and spleen, sublethally (750 
rads) irradiated C57BL/6 (Ly 5.2) mice were injected 
intravenously with 5 x IO6 bone marrow cells or 40 X 106 
splenocytes from C57BL/6-Ly 5.1 mice that had been 
treated intraperitoneally with HBSS and 0.1% NMS or 
rhILr7 (10 jxg/injection) twice a day for 7 days. On day 15 
after transfer the thymi and spleens were removed from 
the recipients. The generation of donor-origin cells in the 
thymus and donor-origin B lineage cells in the spleen was 
determined by FCA. The results in Table 2 demonstrate
that the bone marrow from rhIL-7-treated mice had a 21- 
and 13.7-fold decrease in the ability to reconstitute the. 
donor-origin thymocytes and B220+ splenocytes, respec­
tively, early after transfer when compared with cells from 
vehicle control-treated mice. The fold decrease in the 
relative number of precursors on a per organ basis in 
bone marrow from rhIL-7-treated mice compared with 
HBSS and 0.1% NMS-treated mice was similar (18.1-fold 
for thymocytes and 11.9-fold for B220+ splenocytes). In 
contrast, the reconstituting activity of splenocytes from 
rhIL-7-treated mice was not significandy different from 
splenocytes obtained from untreated mice in their ability 
to reconstitute the thymus of irradiated mice compared 
with controls.
A decrease was observed in the ability of splenocytes 
from rhIL-7-treated mice to generate donor-origin B220* 
cells (2.4-fold) in the spleens of recipient mice compared 
with controls (Table 2). However, when the reconstituting 
ability of splenocytes from rhIL-7-treated mice was calcu­
lated on a per organ basis, as shown in Table 2, there was 
actually an increase in the ability of these splenocytes to 
reconstitute the thymus (4.0-fold) and B220+ splenocytes 
(3,2-fold) when compared with the reconstituting ability 
of splenocytes from HBSS and 0.1 % NMS-treated control 
mice.
rhIL-7 administration results in increased cell numbers at 
several stages of B ceil differentiation
As previously reported, rhIL-7 administration expands 
pre-B cell and mature B cell numbers, up-regulates BP-1, 
and increases the numbers of cytoplasmic (i-chain-positive 
cells and the frequency of colony-forming cell-pre-B cells 
[18, 23]. To extend these observations, bone marrow cells 
and splenocytes from HBSS- or rhIL-7-treated mice were 
examined to quantitate specific stages of B cell differen­
tiation by using FCA. The phenotypic markers B220 and 
CD43 were used to identify pre-pro-B cells and pro-B 
cells, which have been reported to express low levels of 
both of these markers [29]. The profiles in Figure 1A 
show the distribution of bone marrow cells and spleno­
cytes from HBSS- or rhIL-7-treated mice based on B220 
and CD43 expression and the box within each profile 
indicates the area that contains pre-pro-B cells and pro-B 
cells. The percentage and numbers of cells within each 
box are shown in Table 3 in the column labeled B220low+
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TABLE 2. Administration of rhIL-7 to Mice Alters the Capacity of Spleen and Bone Marrow Cells to Regenerate Lymphoid Cells in Irradiated
Recipients
Donor
treatment
(organ)
Cellularity 
of donor 
organ after 
treatment
(xl0’6)a
No. of donor
cells
injected
(xlC6)
No. of
donor
thymocytes
generated/
thymus
(k10'61_________________________
No. of 
donor B220+ 
splenocytes 
generated/ 
spleen
(X llf t ______________________
Total no. lymphoid cells 
generated by donor cells on 
a per ornan basis^
Thymocytes
(xlO6)
B220 splenocytcs 
(xlO-6)
HBSS-bone marrow 19 5 60.9 ± 19.1 59.1 ± 13.8 231.5 ± 72.7 244.4 ± 52.4
rhIL-7‘bone marrow 22 5 2.9 ± 3.5C 4.3 ± 0.3C 12.8 ± 15.5e 18.9 + 1.6e
HBSS-spleen 55 40 41.4 ± 19.6 14.9 ± 4.4 56.9 ± 26.9 J 20.4 ± 6.1
rhIL-7-spleen 420 40 21.7 ± 9.4 6.3 + 0.3d 227.5 ± 98.5 65.8 ± 3.4'
Donor C57BL/6-Ly 5.1 mice (5-25/group) were treated as described in Table 1. After treatment donor bone marrow or spleen cells were 
injected intravenously into sublethally (750 Tads) irradiated C56BL/6 (Ly 5.2) recipients. Fifteen days after transfer the thymi and spleens from S 
mice/group were assayed by using FCA to determine the number of donor-origin cells in the thymus or the number of donor-origin B220+ cells 
in the spleen of recipient mice. Data represent the mean ± SD.
flResults indicate the number of cells from a pool of mice divided by the number of mice.
^These data were calculated by multiplying the number of donor thymocytes or B220* splenocytes per recipient spleen by the total mean 
cellularity of the donor organ (column 2) and dividing by the number of donor cells injected.
Significantly different from HBSS-treated controls (P<,01).
^Significantly different from HBSS-treated controls (P<.Q5).
^Significantly different from HBSS-treated controls (Pc.OOl).
CD43low4\ Bone marrow and spleens from rhIL-7-treated 
mice had an approximately two- to threefold increase in 
the numbers of these cells compared with controls.
The expression of CD2 in combination with B220 and 
surface Ig|i expression was also examined on the bone 
marrow cells and splenocytes from HBSS- or rhIL-7- 
treated mice. All surface Igji-positive B cells expressed 
CD2 in both HBSS- and rhIL-7-treated mice (data not 
shown). Work by Sen et al, [30] showed that CD2 is 
expressed not only on mature B cells but also on pre-B 
(surface Ig|r, B220+) cells expressing cytoplasmic (¿-chain. 
Therefore, the expression of CD2 on surface Ig|J.-negative 
cells was also quantitated. The profiles shown in Figure 
IB illustrate the distribution of B220 and CD2 on surface 
Ig^ L-negative cells from the bone marrow and spleen of 
HBSS- or rhIL-7-treated mice. The corresponding per­
centages and numbers given in Table 3 demonstrate that 
less than 5% of total bone marrow cells from HBSS- 
treated mice are surface Ig(T, B220+, CD2* cells. However, 
bone marrow cells from rhIL-7-treated mice have an 11.6- 
fold increase in the numbers of these cells. Spleen cells 
from HBSS-treated mice have virtually no cells of this 
phenotype. However, 9.99% (26.53 x 106) of total spleno­
cytes are surface Ig^ l", B220+, CD2' after rhIL-7 administra­
tion.
Pre-pro-B cells and pro-B cells are contained the in the 
surface Ig|r, B220+, CD2* cells. When the percentage of 
B220low+, CD43low+ cells that contain pre-pro-B cells and 
pro-B cells is subtracted from the surface Igjj;, B220+, 
CD2' cell percentage, 36% (13.78 x 106) of total bone 
marrow cells from rhIL-7-treated mice remain. This dem­
onstrates that the majority of the cell expansion in the 
surface Igp;, B220+, CD2‘ subset was not due to pre-pro-B 
cells or pro-B cell expansion but due to a disproportion­
ate expansion of another B lineage stage, most likely pre- 
B cells that do not express CD2. Similar results were 
obtained for splenocytes from rhIL-7 mice. After rhIL-7 
administration, there was a 10.8- and 45.8-fold increase in 
the numbers of cells in the surface Igjr, B220+, CD2+ B 
lineage cell subset in the bone marrow and spleen, respec­
tively, compared with HBSS controls.
rhIL-7 accelerates lymphoid regeneration in lethally 
irradiated mice given a bone marrow transfer from 
normal mice
C57BL/6 (Ly 5.2) mice were lethally (900 rads) irradiated 
and injected with 10 x IO6 bone marrow cells from un­
treated C57BL/6-Ly 5.1 congenic mice. After transfer 
recipient mice were injected intraperitoneally with HBSS 
and 0.1% NMS or 5 |Llg of rhIL-7 twice a day throughout 
the course of the experiment. At varying times after trans­
fer, recipient mice were examined by FCA to determine 
the amount of donor-origin myeloid reconstitution in the 
spleen. Administration of rhIL-7 resulted in a minor en­
hancement in myeloid reconstitution compared with 
bone marrow recipients treated with HBSS and 0.1% 
NMS (Fig. 2).
In a similar experiment, FCA was used to determine 
the total number of donor-origin cells generated and the 
amount of donor-origin T cell and B cell reconstitution in 
the spleen. The generation of donor-origin splenocytes 
was accelerated in recipient mice that received rhIL7 
treatment (Fig, 3). Recipient mice treated with HBSS and 
0.1% NMS took up to 4 weeks longer to reach equivalent 
levels of reconstitution. Donor-origin subset analysis in 
the recipients’ spleens was performed using FCA. Exami­
nation of donor-origin B cell numbers in Figure 4 and 
donor-origin T cell numbers in Figure 5 demonstrate that 
treatment of bone marrow recipient mice with rhIL-7 
greatly enhanced the speed of reconstitution of both the 
B cell and T cell compartments by up to 4 and 2 weeks, 
respectively, compared with bone marrow recipients 
treated .with the vehicle control. CD4/CD8 analysis indi­
cated that both the helper CD4+ T cells as well as the 
cytotoxic CD8+ T cells underwent this expansion (Table
4). However, administration of rhIL-7 appeared to prefer­
entially expand the CD8+ T cells, which we have pre­
viously described when normal mice are treated with
rhIL-7 [20, 23].
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Fig. 1. Administration of rhIL-7 to mice results in expansion of several B lineage subsets. C57BL/6-Ly 5.1 mice were injected intraperitoneally twice 
a day for 7 days with HBSS or 10 |Xg of rhIL-7/injection. The day after cessation of treatment the spleen and bone marrow cells were removed and 
labeled for FCA with FITC-CD43 and phycoerythrin-B220 (A) or FITC-CD2, phycoerythrin-B220, and biotin anti-mouse Igji. antibody developed with 
streptavidin-REDß7o (B). The profiles in B illustrate the expression of B220 and CD2 on Ig|T cells. Cells were prepared from a pool of 3 tissues/group,
DISCUSSION
The effects of rhIL-7 on lymphoid and myeloid progeni­
tors and on lymphoid and myeloid lineage repopulation 
were investigated by using C57BL/6 congenie mice. Re­
combinant human IL-7 treatment markedly influenced 
the ability of bone marrow and spleen cells to generate 
CFU-S when transferred into irradiated recipients result­
ing in a 3.4-fold reduction or a 23.6-fold increase in the 
capacity of bone marrow or spleen cells, respectively, to 
form day 9 CFU-S generated from precursors thought to 
be committed to a particular lineage [31]. Furthermore, 
day 12 CFU-S-generating capacity that arises from uncom­
mitted precursors [31] was increased 15.5-fold in spleno­
cytes from rhIL-7-treated mice. Although our previous 
data [2 1] demonstrated that localization of myeloid pro­
genitors capable of generating CFU-c and CFU-GEMM is 
affected by rhIL-7 administration, the results presented 
here extend these observations to show that the numbers 
and localization of the earliest detectable 
erythro/myeloid progenitors also are affected by in vivo 
rhIL-7 treatment.
Because in vivo administration of rhIL-7 had pro­
nounced effects on various stages of myeloid progenitors, 
we also examined its effects on lymphoid progenitors. 
The results presented here are the first demonstration 
that rhlL-7 administration to mice also affects localization
of lymphoid precursors. Specifically, on a per organ basis, 
bone marrow from mice treated with rhIL-7 for 7 days 
had an 11.9- and 18.1-fold decrease in the ability to recon­
stitute the B and T lineages, respectively, in irradiated 
recipients. However, the spleens from rhIL-7-treated mice 
had a three- to fourfold increase in their ability to repopu­
late the lymphoid lineages. These effects were reversible 
and dependent on the length of rhIL-7 treatment (data 
not shown). Thus, in vivo administration rhIL-7 signifi­
cantly affects the localization and numbers of both lym­
phoid and myeloid precursors and, moreover, recent 
results from our laboratory suggest that similar effects of 
rhIL-7 administration on the stem cell compartment oc­
cur as well [32].
The mechanisms by which IL-7 exerts its effects are not 
clear, however, these data combined with previously pub­
lished results suggest that IL-7 may act (directly or indi­
rectly) first by mobilizing precursor cells to extra 
medullary sites. This hypothesis is supported by the sub­
stantial IL-7-induced reduction in precursor cells in the 
bone marrow that coincide with an increase in those cells 
in the spleen. The second component of the IL-7-induced 
effect is probably due to the induction of differentiation 
and expansion of the number of precursors that result in 
increased numbers of mature lymphoid and myeloid line­
age cells. Additional experiments are in progress to ad­
dress these issues.
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TABLE 3. Administration of rhIL-7 Expands B Cell Lineage Subsets
B lineage phenotypic subset
Treatment B220low+ CD431qw+ IgjiiT, B220+, CD2' IgR, B220* 
CD2+
»
Grouo % N o. (x lO 'S % _ _ No. ixl0‘6i _ ... _ _ . . .  , . . No. M0*)
HBSS-bone marrow 2.79 0.81 4.69 1.36 3.85 1.12
rhIL-7-bone marrow 5.00 1.93 40.71 15.71 31.30 12.08
HBSS-spleen 2.79 1.59 0.24 0.14 3.20 1.82
rhIL-7-spleen 2.18 5.79 9.99 26.53 31.41 83.42
The FCA profiles illustrated in Figure 1 were analyzed to determine the percentage of cells bearing indicated phenotypic markers. The data 
presented here show the percentages and also the calculated cell numbers for each subset. The percentages listed indicate the percentage of a 
particular subset based on the total splenocyte or bone marrow cell population.
In addition to documenting the effects of rhIL-7 ad­
ministration on the ability of progenitors to repopulate 
cells of the B lineage, we also examined the effect of 
rhIL-7 on specific stages of B cell differentiation, as de­
fined by phenotypic markers using FCA. The results pre­
sented here demonstrate that pre-pro-B cells and pro-B 
cells expand in number by two- to threefold in the spleen 
and bone marrow of rhIL-7-treated mice. This supports 
the work of Hardy et al. [29], demonstrating in vitro that 
CD43low+ cells respond to IL-7. The expansion of cells in 
other B lineage stages after rhIL-7 treatment is even more 
dramatic. Pre-B cells (surface Igji', B220+) that expressed 
CD2 expanded 10 .8- to 45.8-fold, depending on the organ 
examined. After rhIL-7 treatment surface Ig|r, B220+, 
CD2' cells expanded by I I .6-fold in the bone marrow and 
to 26.53 X 106 cells in the spleen. This expansion of 
surface Igjr, B220+, CD2' cells cannot be accounted for by 
the expansion of the pre-pro-B and pro-B cell populations 
also contained in this subset. It is probable that the cells 
that are responsible for the majority of the expansion are 
in a stage between the pro-B cell and the classic pre-B cell, 
which expresses cytoplasmic [i-chain and CD2. The exact
10
9
o
20
®
O
+
VO
O
00
c
'5>
n
O
I
oa
o
a
15
10
©
B
3
z
0
HBSS
rhiL-7
J--L J_I_L J--U_I_1---L— A. J ---- 1_____ I_____ I----L — 1 ■J----■ < I ■ - «
0 14 21 28 35 42
Number of Days After Bone Marrow Ceil Transfer
Fig. 2. Administration of rhIL-7 to recipient mice given a bone marrow 
transfer results in minimal acceleration of donor-origin myeloid reconsti­
tution. Lethally (900 rads) irradiated C57BL/6 (Ly 5.2)-recipient mice 
were injected intravenously with 10 x IO6 bone marrow cells from 
C57BL/6-Ly 5.1 congenic mice. After cell transfer recipients received 
HBSS and 0.1% NMS (O) or 5 i^g of rhIL-7 ( • )  intraperitoneally twice a 
day throughout the course of the experiment. At varying times after 
transfer the splenocytes from recipient mice were examined by FCA to 
determine the number of donor-origin myeloid cells using the antigranu­
locyte mAb RB6-8C5. The data points indicate the mean ± SD of 3 
mice/group. Asterisks indicate statistical significance; P<.01 compared 
with HBSS for days 17 and 36 and iKOOl for day 42. In normal adult 
mice there are approximately 5% granulocytes in the spleen. This corre- 
sponds to 3 x 10fa to 4 x 106 granulocytes, dependingon spleen cellularity.
placement of this cell within the stages of B cell differen­
tiation will most likely require the examination of its 
status in terms of Ig gene rearrangement. Because this 
cell subset is present in low numbers in normal bone 
marrow cells, the use of this IL-7 model may be important 
in better understanding the complexities of B cell differ­
entiation. Thus, it appears that rhIL-7 administration 
either directly or indirectly results in expansion of cells at 
several stages of B cell differentiation from the pre-pro-B 
cells through to B cells.
In comparing the reconstitution data with the FCA 
data, it is quite clear that although rhIL-7 administration 
expands B lineage stages from the pre-pro-B cells and 
onward in the bone marrow, the precursor responsible 
for B cell reconstitution is not increasing in the bone 
marrow (Table 2). There are several possible explanations 
to account for this. One possibility is that precursors 
responsible for reconstitution have migrated from the 
bone marrow to the spleen and this has been addressed 
above. A second possibility is that the cells are rendered 
inactive by IL-7 either by functional inhibition or death. 
This is unlikely based on our results demonstrating that 
rhIL-7 accelerates B cell reconstitution after normal bone 
marrow transplantation. A third possibility is that the cells
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Fig. 3. Administration of rhIL-7 to recipient mice given a bone marrow 
transfer results in accelerated reconstitution of donor-origin splenocytes. 
In a similar experiment to that described in Figure 2 the number of 
donor-origin cells (C57BL/6-Ly 5.1) contained in the spleens of recipient 
C57BL/6 (Ly 5.2) mice was quantitated by FCA at varying times after 
bone marrow transfer. Recipient mice that received HBSS and 0.1% NMS 
or 5 fig of rhIL-7 are indicated by (O) or (•), respectively. The data points 
indicate the mean ± sd of 3 mice/group. Asterisks indicate statistical 
significance; Pc.01 compared with HBSS for days 13,17, and 23. In normal 
adult mice there are approximately 60 x 106 to 80 x 106 cells in the spleen 
after removal of red blood cells.
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TABLE 4. Both CD4+ and CD8+ Donor-Origin T Cells Expand in Number in Irradiated Recipients After Bone Marrow Transfer and rhIL-7
Administration
Treatment 
of recipient
Days after 
transfer
-6
No, oF donor-orgin T cells/subset (xlO ) 
CD4+ CD8+
CD4:CD8
ratio
HBSS 13 0.4 ± 0.1 0.7 ± 0.2 0.6:1
rhIL-7 13 2.4 ± 0.6a 4.7 ± 0.8“ 0.5:1
HBSS 17 0.9 ± 0.3 0.7 ± 0.1 1.3:1
rhIL-7 17 2.9 ± 0.2 5.7 ± 0.9* 0.5:1
HBSS 23 1.6 ± 0.3 1.3 ± 0.3 1.2:1
rhIL-7 23 4.8 ± 1.1“ 7.0 ± 2.8C 0.7:1
HBSS 41 17.5 ±7.1 7.2 ± 1.7 2.4:1
rhIL-7 41 16.7 ± 7.9 15.4 ± 6.7 1.1:1
Donor-origin splenic T cells shown in Figure 5 were further analyzed by FCA to determine the number of cells contained in the CD4+ and 
CD8+ subsets. Data represent the mean ± SD of 3 mice/group.
“Significantly different from HBSS-treated controls (Pc.Ol).
^Significantly different from HBSS-treated controls (P< .001).
^Significantly different from HBSS-treated controls (P<.05),
that are capable of repopulating the B cell lineage have 
been used to support the dramatic expansion of pre-pro-B 
cells to mature B cells and are thus depleted. The recon­
stitution data support this possibility in that these precur­
sors appear to be essential for the B cell expansion in 
bone marrow-transplanted mice.
Because IL-7 generated a leukocytosis in normal mice 
[18, 23] and accelerated lymphocyte repopulation in cy­
clophosphamide-treated mice [19] and sublethally irradi­
ated mice [20], its potential application in accelerating 
myeloid and/or lymphoid reconstitution after bone mar­
row transplantation was studied in the C57BL/6 Ly 5 
congenic mouse model. Lethally irradiated mice that had 
received normal donor-origin bone marrow cells and
4Û
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Fig. 4. Administration of rhIL-7 to recipient mice given a bone marrow 
transfer results in accelerated reconstitution of donor-origin B cells. In 
the experiment described in Figure 3 the splenocytes from recipient mice 
were examined by FCA to determine the number of donor-origin B cells. 
Recipient mice that received HBSS and 0.1% NMS or 5 |ig of rhIL-7 are 
indicated by (O) or (•), respectively. The data points indicate the mean 
± SD of 3 mice/group. Asterisks indicate statistical significance; /KOI 
compared with HBSS for days 13 and 17 and P <.02 for day 23. In normal 
adult mice there are approximately 45% B cells in the spleen. This 
corresponds to 27 x 106 to 36 x 106 B cells, depending on spleen cellularity.
were treated with rhIL-7 had somewhat enhanced 
myeloid reconstitution in mice treated with rhIL-7. How­
ever, lymphoid reconstitution was both accelerated and 
enhanced for both donor-origin T cells and B ceils. By 13 
days after bone marrow transfer there was a 3.4-fold in­
crease in B cell reconstitution in recipients treated with 
rhIL-7 compared with those that had received only HBSS 
and 0.1% NMS. There was also a fourfold increase in the 
number of T cells generated in recipient mice treated 
with rhIL-7 compared with controls until at least the 3rd 
to 4th week after transfer when reconstitution of T cells 
in control mice began to approach that of the rhlL-7- 
treated group. Furthermore, there was no observeable 
toxic effect of long-term (6 weeks) rhIL-7 treatment in
<0
Number of Days After Bone Marrow Cell Transfer
Fig. 5. Administration of rhIL-7 to recipient mice given a bone marrow 
transfer results in accelerated reconstitution of donor-origin T cells. In 
the experiment described in Figure 3 the splenocytes from recipient mice 
were examined by FCA to determine the number of donor-origin T cells 
at varying times after transfer. Recipient mice that received HBSS and 
0.1% NMS or 5 |ig of rhIL-7 are indicated by (O) or (•) , respectively. The 
data points indicate the mean ± sd  of 3 mice/group. Asterisks indicate 
statistical significance; Pc.01 compared with HBSS for day 13, P< .001 for 
day 17, and P< .05 for day 23. In normal adult mice there are approxi­
mately 35% T cells in the spleen. This corresponds to 21 x 10(i to 28 x 106 
T cells, depending on spleen cellularity.
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these experiments, unlike the study of Fraser et al. [33] in 
which 23% of lethally irradiated recipient mice that had 
received bone marrow infected with a retrovirus express­
ing the m.IL-7 gene were moribund within 4-16 weeks 
after transplantation. These data illustrate that rhIL-7 ad­
ministration is able to accelerate bone marrow engraft­
ment after transplantation.
The results presented here demonstrate that IL-7 has 
potent effects on lymphoid and myeloid mobilization and 
accelerates bone marrow engraftment in lethally irradi­
ated recipients. Thus, IL-7 administration may be impor­
tant in the enhancement and acceleration of lymphoid 
and myeloid regeneration in myeloablated cancer pa­
tients who subsequently receive bone marrow transplants.
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